Anti-Cancer Treatment with C-Terminal p53 Palindromic Peptide that Induces Apoptosis of Cells with Aberrant p53
Anti-Cancer Treatment with C-Terminal p53 Palindromic Peptide that Induces Apoptosis of Cells with Aberrant p53
The invention identified two polypeptides comprising a given segment of continuous amino acids or at least two of each covalently linked to each other. These polypeptides activate the DNA binding activity of p53 and thus activate the cellular functions of p53, enable their use as pharmaceutical compositions in a variety of therapeutic regimens, which permits the arrest of the growth or proliferation of tumor cells or apoptosis of tumor ...
New York, NY, United States
Overview Comments Tagged publications

Background

Cancers Caused By Mutations in Peptide Involved in Cell Growth Regulation: More than 50% of human malignancies, including breast cancers, are associated with missense mutations or deletions of p53, a sequence-specific transcriptional factor involved in cell growth regulation. Therefore, a therapy directed at specifically killing p53-mutant cells would have wide application in targeted cancer therapies. The invention provides a method of killing cancer cells that contain aberrant p53 using a plasmid that expresses a specific peptide sequence. This polypeptide could induce p53-dependent, apoptotic cell death in the presence of mutant p53 with minimal effect on cells with normal levels of wild-type 53, which could be used for cancer chemotherapy or chemoprophylaxis. 

Anti-Cancer Drug Therapies from Killing Mutant Peptides: The invention identified two polypeptides comprising a given segment of continuous amino acids (SEQ ID NO: 1, SEQ ID NO: 2) or at least two of each covalently linked to each other. These polypeptides activate the DNA binding activity of p53 and thus activate the cellular functions of p53, enable their use as pharmaceutical compositions in a variety of therapeutic regimens, which permits the arrest of the growth or proliferation of tumor cells or apoptosis of tumor cells. The invention also defines the composition and the methods to systemically, or locally administer polypeptides to the site of the tumor.

Applications: • Novel therapeutic pharmaceutical compositions and methods for aberrant p53 targeted anti cancer treatment • Novel treatment for patients with cancer to enhance the tumor suppressor functions of p53, whether wild-type or mutant p53 is present in tumor cells 

Advantages: • Novel chemotherapeutic treatment targeted on aberrant p53, which has broad application on different cancers • The advanced administration method is not affected by proteolytic extracellular breakdown and does not generate immune responses 

Publications: Fine RL.et al. Mol Cancer Ther. 2006 5(1):20-8. Fine RL.et al. J Biol Chem. 2007 14;282 (37):26675-86.

Lead Inventors: Robert L. Fine; Paul Brandt-Rauf; Yueha Mao



No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
  • Gene therapy for inflammatory and autoimmune diseases
  • This technology comprises inhibitors of antibody production, including IgG, IgA and IgE. These peptide inhibitors are derived from naturally occurring mutations in the CRAF1 (TRAF-3) gene and they specifically inhibit CD40 mediated intracellular signaling. As the CD40-mediated signaling pathway is necessary for B-cell proliferation and antibody production, inhibitors of this pathway act as highly specific and effective immunosuppressants.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
  • Parkinson's and Huntington's Treatment
  • This technology is an antisense oligonucleotide to the protein Nedd2. Nedd2 is an aspartase expressed by neuronal cells and plays a crucial role in apoptosis. When neurons are deprived of cytokines such as nerve growth factor (NGF), Nedd2 expression is upregulated as part of the apoptotic pathway. This technology is an antisense oligonucleotide (ANedd) capable of blocking expression of Nedd2, thereby inhibiting apoptosis.
  • Read more
  • TherapeuticsResearch materials
  • New York, NY, United States
  • Stanford University
Back
or
Back
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 336

Send Us a Message